Last reviewed · How we verify
ONO-1110
At a glance
| Generic name | ONO-1110 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of ONO-1110 in Patients With Fibromyalgia (PHASE2)
- A Study of ONO-1110 in Patients With Postherpetic Neuralgia (PHASE2)
- A Study of ONO-1110 in Patients With Major Depressive Disorder (PHASE2)
- A Study of ONO-1110 in Patients With Social Anxiety Disorder (PHASE2)
- A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-1110 CI brief — competitive landscape report
- ONO-1110 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI